Background: Skin cancer is the most common cancer in the United States. Inc
reasing evidence suggests that screening for malignant melanoma is effectiv
e, but its cost-effectiveness has not been determined.
Objective: We attempted to determine the effectiveness and costs of a visua
l screen to diagnose malignant melanoma in high-risk persons.
Methods: We developed a decision analysis comparing no skin cancer screen w
ith a single screen by a dermatologist. Clinical outcomes included malignan
t melanoma, nonmelanoma skin cancer, or no skin cancer. Life expectancy and
costs of care were projected on the basis of clinical findings.
Results: Skin cancer screening increased average discounted life expectancy
from 15.0963 years to 15.0975 years. Based on the prevalence of malignant
melanoma, however, this translates into an increased discounted life expect
ancy of 0.9231 years for each person with diagnosed melanoma. Using a cost
of $30 per screen, total skin cancer-related costs for a cohort of 1 millio
n people increased from $826 million with no screen to $861 million with sc
reening, with an increase of 1200 years of life. This results in an increme
ntal cost-effectiveness ratio of $29,170 per year of life saved (YLS) with
screening. Sensitivity analysis showed that the cost-effectiveness ratio fo
r screening remained below $50,000/YLS if the prevalence of melanoma in the
screened population was at least 0.0009, the probability that a melanoma d
etected in screening was localized was at least 94.8%, or the cost of each
screen was below $57.
Conclusion: Skin cancer screening in high-risk patients is likely to be ass
ociated with a small increase in discounted life expectancy and is reasonab
ly cost-effective compared with other cancer screening strategies.